The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy Virtual 2020 | MRD as a tool to discontinue therapy in MM?
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses measurable residual disease (MRD) as a tool to discontinue therapy in multiple myeloma (MM). Dr Costa reveals that the next desired development in MM is to be able to use the dynamic prognostic information that MRD provides and repurpose it to make treatment decisions. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
